Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Operating Income Loss of -$5.29 million for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -16.8% in Operating Income Loss from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Operating Income Loss has grown by 57.0%.
- Historical annual values: Fiscal year 2025: -$5.29 million | Fiscal year 2024: -$4.53 million | Fiscal year 2023: -$2.90 million | Fiscal year 2022: -$3.43 million | Fiscal year 2021: -$4.67 million | Fiscal year 2020: -$4.96 million | Fiscal year 2019: -$6.30 million | Fiscal year 2018: -$8.05 million | Fiscal year 2017: -$13.32 million | Fiscal year 2016: -$24.51 million | Fiscal year 2015: -$24.65 million | Fiscal year 2014: -$12.63 million | Fiscal year 2013: -$13.03 million | Fiscal year 2012: -$14.34 million | Fiscal year 2011: -$21.44 million | Fiscal year 2010: -$20.69 million | Fiscal year 2009: -$12.33 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: